The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Anthracyclines Disrupt Ca2+ Signalling In Cardiomyocytes: A Contribution To Cardiac Toxicity
Funder
National Health and Medical Research Council
Funding Amount
$525,620.00
Summary
Anthracyclines are one of the most effective drugs used in chemotherapy, but cause side effects resulting in serious heart problems which can be fatal. The link between anthracycline therapy and the problems they cause in the heart is not fully defined. We will investigate mechanisms leading to these side effects and define specific targets of anthracyclines in the heart. It is hoped this will lead to the design of new drugs which counteract the side effects of anthracycline treatment.
New CaMKII Therapeutic Targets In Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$740,335.00
Summary
Deaths associated with impaired heart muscle relaxation and unstable cardiac cycle rhythm are increasing. The mechanisms by which these pathologies occur are not understood and clinical therapies are lacking. We have novel evidence to suggest that a key signalling protein, CaMKII, is critically involved in the development of these forms of heart pathology. This goal of this project is to identify how CaMKII is implicated in heart failure and dysrhythmia as a basis for designing new therapies.
Optimising Efficacy Of A Peptide Derived Against The Alpha-interacting Domain Of The L-type Calcium Channel In Reduction Of Ischemia-reperfusion Injury
Funder
National Health and Medical Research Council
Funding Amount
$405,063.00
Summary
A heart attack is associated with an increase in free radicals and calcium in heart muscle cells. The function of the L-type calcium channel, a protein responsible for calcium entry into cells, is altered by free radicals and this contributes to the development of heart disease. We now have considerable proof of concept that a peptide derived against the L-type calcium channel can decrease heart injury. We will optimise efficacy and delivery of the peptide to prevent heart failure.
Identifying The Site/s Of Modification On The Human L-type Ca2+ Channel Protein Isoforms During Oxidative Stress With Reference To Development Of A Therapeutic Target
Funder
National Health and Medical Research Council
Funding Amount
$360,369.00
Summary
A rise in calcium and free radicals in the heart are associated with the development of heart disease. We have good evidence that a protein in the heart muscle known as the L-type calcium channel mediates changes in calcium in response to free radicals. This proposal will identify how the channel function is altered by free radicals so that a therapeutic target can be designed to prevent altered channel function and development of heart disease during increases in free radicals.
The Role Of The Cytoskeleton In Communication Between The L-type Ca2+ Channel And The Mitochondria In Cardiac Pathology
Funder
National Health and Medical Research Council
Funding Amount
$542,890.00
Summary
The L-type calcium channel is a protein in the membrane of heart muscle cells responsible for maintaining normal rhythm and contraction. We have shown that the channel can also regulate the function of the energy producing part of the cell (mitochondria). This occurs with the assistance of proteins that maintain cell architecture. We will test whether this association is altered in human disease where the cell architecture is disrupted to determine the mechanisms for poor energy supply.
Characterising The Effects Of Oxidative Stress On The Human L-type Ca2+ Channel Isoforms And Role In Human Pathology
Funder
National Health and Medical Research Council
Funding Amount
$250,805.00
Summary
Oxidative stress, poor energy production and increases in intracellular calcium are features of the failing heart. I have determined that the function of the L-type calcium channel, the primary protein responsible for calcium influx and contraction can be regulated by free radicals produced by the mitochondria (powerhouse of the cell). This proposal will determine the site of modification on the human L-type calcium channel and how communication between the channel and the mitochondria is altere ....Oxidative stress, poor energy production and increases in intracellular calcium are features of the failing heart. I have determined that the function of the L-type calcium channel, the primary protein responsible for calcium influx and contraction can be regulated by free radicals produced by the mitochondria (powerhouse of the cell). This proposal will determine the site of modification on the human L-type calcium channel and how communication between the channel and the mitochondria is altered in animal models of human disease.Read moreRead less
Control Of Cardiac And Skeletal Contractility By Luminal Calcium Store Load In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$415,138.00
Summary
Disorders affecting skeletal muscle and the heart can have life threatening effects and lead to impaired mobility and sudden cardiac death. This project will uncover the mechanisms of disorders which lead to skeletal muscle fatigue, chemotherapy induced toxicity in the heart and heart failure. Understanding these mechanisms may lead to successful gene therapy treatment and to the design of a new range of drug therapies to treat these devastating disorders.
Genetic Basis Of Sudden Cardiac Death In The Young
Funder
National Health and Medical Research Council
Funding Amount
$574,500.00
Summary
Sudden cardiac death is a devastating complication of a variety of cardiovascular disorders. In the young, sudden cardiac death can be caused by both structural abnormalities of the heart, e.g. cardiomyopathies, and electrical abnormalities of the heart, such as familial long QT syndrome. In most young sudden cardiac deaths, these cardiovascular disorders are caused by underlying gene abnormalities which place individuals at a higher risk of sudden death. The aim of this project is to understand ....Sudden cardiac death is a devastating complication of a variety of cardiovascular disorders. In the young, sudden cardiac death can be caused by both structural abnormalities of the heart, e.g. cardiomyopathies, and electrical abnormalities of the heart, such as familial long QT syndrome. In most young sudden cardiac deaths, these cardiovascular disorders are caused by underlying gene abnormalities which place individuals at a higher risk of sudden death. The aim of this project is to understanding the genetic basis of sudden cardiac deaths in the young. In particular, the study will identify and characterise the specific genes which cause sudden cardiac death, and what the underlying mechanism is regarding how a single gene defect can lead to such a devastating clinical outcome. Understanding the various cardiovascular diseases that cause sudden death, clinically screening at-risk individuals, coupled with the initiation of appropriate therapeutic and preventative strategies such as implantation of cardioverter defibrillators will most likely reduce the incidence of sudden cardiac death in the young of our community. Elucidation of the underlying genetic defects which cause many of these cardiac disorders will substantially improve diagnostic accuracy, will be invaluable for genetically screening at-risk individuals and by making the diagnosis earlier in life, will create a larger therapeutic window to allow initiation of therapies to prevent complications of disease, including sudden death.Read moreRead less
How Does Sudden Cardiac Death Occur In Familial Hypertrophic Cardiomyopathy?
Funder
National Health and Medical Research Council
Funding Amount
$1,312,606.00
Summary
Familial hypertrophic cardiomyopathy is a leading cause of sudden cardiac death but the mechanisms for the induction of arrhythmia are unknown. This proposal has the potential to impact sudden death in the young and enable significant expansion of Australia’s research capacity into the treatment of familial hypertrophic heart disease in humans.